CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for BioXell S.p.A. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

BioXell S.p.A.
Via C. Colombo 1
Phone: +39 02 9333 7614p:+39 02 9333 7614 Lainate, I – 20020  Italy Ticker: BXLNBXLN
This company was Merged or Acquired on 3/4/2010.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
BioXell SpA is an Italy-based biopharmaceutical company. The Company focuses on the research, development and commercialization of therapies for various medical needs. It is active in a range of therapeutic areas, such as urology (benign prostatic hyperplasia, overactive bladder and male infertility), inflammation (sepsis, inflammatory bowel disease, post-surgical adhesions), pain and other therapeutic areas (secondary hyperparathyroidism and osteoporosis). BioXell S.p.A’s products, which are in the preclinical and development phases, include Elocalcitol and BXL746, a Vitamin D3 analogues for the treatment of urological disorders; MNAC13 applied for treatment of chronic pain, and TREM-1, for the treatment of sepsis. The Company has one wholly owned subsidiary, BioXell Inc that develops the Vitamin D3 platform.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/200912/31/2009Yes----

Industries
SIC Code Description
5122 Drugs, drug proprietaries, and druggists' sundries

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board Thomas D.Szucs 50 11/1/2006 1/1/2004
Chief Executive Officer NielsAckermann 36 4/27/2009
Chief Administrative Officer AlviseSagramoso 1/1/2007 3/1/2002
5 additional Officers and Directors records available in full report.

General Information
Number of Employees: 20 (As of 6/30/2009)
Outstanding Shares: 5,381,577 (As of 12/31/2009)
Stock Exchange: SWF
Fax Number: +39 02 9333 7663


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023